CMMB Chemomab Therapeutics Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1534248 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY35.5%
TTM EPS YoY-53.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-69.5%
ROA-58.5%
ROIC (approx.)-1,446.2%
Asset turnover—
Leverage & solvency
Liabilities / assets10.7%
Debt / equity0.00x
Current ratio9.08x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.24x
Accruals ratio13.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q22024-06-30 | 2024Q12024-03-31 | 2023Q22023-06-30 | 2023Q12023-03-31 | 2022Q4*2022-12-31 | 2022Q32022-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | — | — | $2.93M | — | $5.02M | $6.89M | $5.89M | $5.42M |
| SG&A expense | — | — | $840,000 | — | $3.17M | $2.16M | $2.75M | $2.89M |
| Pretax income | — | — | -$3.63M | — | -$7.94M | -$8.73M | -$8.26M | -$8.08M |
| Income tax | — | — | $0 | — | $34,000 | $21,000 | $10,000 | $0 |
| Net income | -$2.06M | -$3.32M | -$3.63M | -$3.87M | -$7.97M | -$8.75M | -$8.27M | -$8.08M |
| EPS (basic) | — | — | 0.01 | — | 0.04 | 0.04 | — | 0.04 |
| EPS (diluted) | — | — | 0.01 | — | 0.04 | 0.04 | — | 0.04 |
| Weighted avg. shares (diluted) | — | — | 286.08M | — | 221.67M | 221.00M | — | 228.77M |
| Balance sheet | ||||||||
| Cash & equivalents | $5.45M | — | $5.11M | — | $10.46M | $20.77M | $13.60M | $10.74M |
| Current assets | $10.61M | — | $13.46M | — | $27.70M | $33.78M | $41.74M | $48.73M |
| PP&E, net | $217,000 | — | $276,000 | — | $338,000 | $352,000 | $367,000 | $380,000 |
| Total assets | $11.13M | — | $14.54M | — | $28.85M | $35.01M | $43.06M | $50.22M |
| Current liabilities | $1.43M | — | $4.31M | — | $6.83M | $7.00M | $6.75M | $5.48M |
| Total liabilities | $1.43M | — | $4.56M | — | $6.86M | $7.06M | $6.84M | $5.59M |
| Shareholders' equity | $9.70M | $10.39M | $9.98M | $13.33M | $21.99M | $27.95M | $36.22M | $44.62M |
| Shares outstanding | 413.85M | — | 287.18M | — | 248.06M | 232.64M | 232.64M | 229.02M |
| Cash flow statement | ||||||||
| Operating cash flow | — | — | — | — | -$7.49M | -$7.19M | -$5.70M | -$5.25M |
| Capital expenditure | — | — | — | — | $2,000 | $1,000 | $1,000 | $42,000 |
| Free cash flow | — | — | — | — | -$7.49M | -$7.19M | -$5.70M | -$5.30M |
| Investing cash flow | — | — | — | — | -$4.27M | $14.43M | $9.35M | $6.07M |
| Financing cash flow | — | — | — | — | $1.37M | $0 | -$869,000 | $39,000 |
| Depreciation & amortization | — | — | — | — | $16,000 | $16,000 | $14,000 | $17,000 |
| Stock-based compensation | — | — | — | — | $639,000 | $484,000 | $740,000 | $836,000 |
Free plan shows the latest 8 periods; Pro shows all 22 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.